Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Alliance Pharma plc

Healthcare GB APH

NoneGBX
0.00(0%)

Last update at 2025-06-13T16:00:04.809529Z

Day Range

--
LowHigh

52 Week Range

33.7071.45
LowHigh

Fundamentals

  • Previous Close 64.70
  • Market Cap212.37M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield3.75%
  • EBITDA36.38M
  • Revenue TTM167.42M
  • Revenue Per Share TTM0.31
  • Gross Profit TTM 101.68M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 5.21M 18.16M 13.02M 31.08M 22.80M
Minority interest - - - - -
Net income 0.94M 7.32M 8.03M 25.01M 18.36M
Selling general administrative 63.59M 63.05M 45.91M 46.81M 41.93M
Selling and marketing expenses - - - - -
Gross profit 101.68M 109.45M 82.82M 86.08M 72.65M
Reconciled depreciation 10.76M 16.25M 20.96M 1.96M 7.79M
Ebit 10.57M 21.57M 27.15M 35.63M 25.84M
Ebitda 20.75M 43.57M 48.11M 38.14M 33.63M
Depreciation and amortization 10.18M 21.99M 20.96M 2.51M 7.79M
Non operating income net other - - - - -
Operating income 10.57M 21.57M 27.15M 35.63M 28.92M
Other operating expenses 138.61M 135.48M 101.43M 98.19M 89.28M
Interest expense 4.79M 3.01M 2.08M 3.29M 3.04M
Tax provision 4.27M 10.84M 4.99M 6.07M 4.45M
Interest income 0.02M 0.02M 0.01000M 0.02M 0.05M
Net interest income -5.41700M -3.62300M -2.64700M -3.75400M -1.43900M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 4.27M 10.84M 4.99M 6.07M 4.45M
Total revenue 167.42M 163.21M 129.80M 135.64M 118.21M
Total operating expenses 72.88M 81.72M 54.44M 48.63M 43.72M
Cost of revenue 65.73M 53.76M 46.98M 49.56M 45.56M
Total other income expense net -5.36100M -3.41800M -14.13300M -4.55300M -6.12100M
Discontinued operations - - - - -
Net income from continuing ops 0.94M 7.32M 8.03M 25.01M 18.36M
Net income applicable to common shares 0.94M 7.32M 8.03M 25.01M 18.36M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 537.41M 503.49M 508.85M 407.64M 403.61M
Intangible assets 400.10M 382.51M 381.61M 312.13M 318.68M
Earning assets - - - - -
Other current assets 0.16M 30.89M 25.42M 31.69M 29.15M
Total liab 249.75M 221.00M 227.90M 133.46M 151.41M
Total stockholder equity 287.66M 282.49M 280.96M 274.18M 252.20M
Deferred long term liab - - - - 0.77M
Other current liab 10.79M 10.19M 17.95M 16.21M 11.00M
Common stock 5.40M 5.38M 5.33M 5.29M 5.18M
Capital stock 5.40M 5.38M 5.33M 5.29M 5.18M
Retained earnings 108.24M 116.42M 117.70M 112.51M 95.10M
Other liab - 61.73M 56.65M 30.21M 29.04M
Good will 21.53M 31.24M 31.26M 16.53M 16.57M
Other assets 4.72M 3.90M 2.82M 2.39M 2.79M
Cash 31.71M 29.06M 28.90M 17.83M 10.89M
Cash and equivalents - - - - -
Total current liabilities 47.02M 40.58M 30.19M 24.21M 91.72M
Current deferred revenue - - - - -
Net debt 102.03M 87.00M 113.12M 62.23M 88.23M
Short term debt 0.61M 0.46M 0.96M 1.02M 68.48M
Short long term debt - - - 0.00000M 68.03M
Short long term debt total 133.74M 116.06M 142.02M 80.06M 99.12M
Other stockholder equity 174.02M 160.69M 157.93M 156.37M 155.66M
Property plant equipment - 4.83M 4.49M 4.21M 3.34M
Total current assets 105.48M 81.02M 77.24M 65.04M 58.75M
Long term investments - - - - -
Net tangible assets - -131.25800M -143.34200M -61.81900M -86.52900M
Short term investments - - - - -
Net receivables 49.32M 30.82M 24.22M 30.29M 27.93M
Long term debt 133.74M 116.06M 138.33M 77.04M 28.67M
Inventory 24.29M 21.07M 22.92M 15.52M 18.71M
Accounts payable 35.62M 29.93M 11.28M 6.97M 8.98M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - -4.96300M -3.74700M
Additional paid in capital - - - - -
Common stock total equity - - 5.33M 5.29M 5.18M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.60M 0.37M 0.68M 0.68M 0.18M
Deferred long term asset charges - - - - -
Non current assets total 431.93M 422.47M 431.61M 342.60M 344.86M
Capital lease obligations 3.83M 2.88M 3.69M 3.02M 2.42M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -17.02500M -4.59900M -85.86400M 0.50M 2.20M
Change to liabilities 7.28M -0.32600M 5.93M -3.80100M 5.06M
Total cashflows from investing activities -17.02500M -4.59900M -85.86400M -3.28400M -59.08300M
Net borrowings 12.70M -23.51100M 60.17M -18.20500M 11.68M
Total cash from financing activities -0.87600M -34.34400M 55.75M -25.19800M 36.59M
Change to operating activities -1.07800M 9.47M 9.47M 9.47M -0.01300M
Net income 0.94M 7.32M 8.03M 25.01M 18.36M
Change in cash 2.65M 0.16M 11.07M 6.94M -0.29100M
Begin period cash flow 29.06M 28.90M 17.83M 10.89M 11.18M
End period cash flow 31.71M 29.06M 28.90M 17.83M 10.89M
Total cash from operating activities 20.97M 38.66M 41.57M 35.76M 22.17M
Issuance of capital stock 0.34M 0.74M 1.64M 4.51M 34.82M
Depreciation 10.76M 16.25M 20.96M 1.96M 7.79M
Other cashflows from investing activities 0.20M 0.20M 0.01000M 0.02M 2.46M
Dividends paid 9.12M 8.60M 2.84M 7.60M 6.35M
Change to inventory -2.20900M 1.84M -5.20600M 2.04M -4.45800M
Change to account receivables -18.72000M -6.14600M 6.73M -0.49800M -7.62800M
Sale purchase of stock - - - - -
Other cashflows from financing activities 9.16M -3.88900M 78.48M -3.57800M 23.93M
Change to netincome 23.35M 15.76M 16.60M 10.85M 8.91M
Capital expenditures 0.61M 5.53M 4.61M 4.16M 2.93M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -14.72600M 4.84M 7.45M -2.26300M -10.04100M
Stock based compensation 0.09M 2.25M 1.37M 1.82M 1.79M
Other non cash items 23.91M 3.62M 2.65M 5.43M 4.28M
Free cash flow 20.36M 33.13M 36.95M 31.60M 19.24M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
APH
Alliance Pharma plc		 - -% - - 7.09 1.29 0.77 1.84 24.99
HLN
Haleon PLC		 2.00 0.60% 336.00 20.24 18.94 2.95 2.02 3.68 14.19
HIK
Hikma Pharmaceuticals PLC		 13.00 0.88% 1495.00 9.73 9.03 0.85 1.45 1.53 6.07
HCM
HUTCHMED China Ltd		 1.25 0.74% 169.25 5.38 19.30 3.37 2.02 2.25 2.40
AGY
Allergy Therapeutics		 0.10 1.19% 8.50 - 106.38 11.72 159.47 12.12 -4.1496

Reports Covered

Stock Research & News

View All

Profile

Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. The company also offers medicines, medical devices, food supplements, and cosmetics. It provides its products under the Aloclair, Anbesol, Asthon and Parsons, Forceval, Hydromol, Kelo-cote, Macushield, Vamousse, Nizoral, and Amberen brand names. Alliance Pharma plc was incorporated in 1996 and is headquartered in Chippenham, the United Kingdom.

Alliance Pharma plc

Avonbridge House, Chippenham, United Kingdom, SN15 2BB

Key Executives

Name Title Year Born
Mr. Andrew Timothy Franklin Interim CEO, CFO & Exec. Director 1966
Mr. Peter Jonathan Butterfield CEO & Exec. Director (Leave of Absence) 1976
Mr. Stephen Kidner Chief Scientific Affairs & Operations Officer NA
Ms. Cora Maeve McCallum C.F.A. Head of Investor Relations & Corp. Communications NA
Mr. Alex Duggan Chief Commercial & Corp. Devel. Officer NA
Ms. Janice Timberlake Chief People & Infrastructure Officer NA
Mr. Steve Lobb Head of Hydromol NA
Mr. David Hope Head of Secondary Care NA
Mr. Rajiv Ghidiyal Head of APAC, EMEA & Americas NA
Mr. Karim Husny Head of International NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions